Cargando…

Synergy between Phage Sb-1 and Oxacillin against Methicillin-Resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) is a notorious pathogen responsible for not only a number of difficult-to-treat hospital-acquired infections, but also for infections that are community- or livestock-acquired. The increasing lack of efficient antibiotics has renewed the interest in...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Kevin, Pier, Wolfgang, Krüttgen, Alex, Horz, Hans-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300854/
https://www.ncbi.nlm.nih.gov/pubmed/34356770
http://dx.doi.org/10.3390/antibiotics10070849
_version_ 1783726544784457728
author Simon, Kevin
Pier, Wolfgang
Krüttgen, Alex
Horz, Hans-Peter
author_facet Simon, Kevin
Pier, Wolfgang
Krüttgen, Alex
Horz, Hans-Peter
author_sort Simon, Kevin
collection PubMed
description Methicillin-resistant Staphylococcus aureus (MRSA) is a notorious pathogen responsible for not only a number of difficult-to-treat hospital-acquired infections, but also for infections that are community- or livestock-acquired. The increasing lack of efficient antibiotics has renewed the interest in lytic bacteriophages (briefly phages) as additional antimicrobials against multi-drug resistant bacteria, including MRSA. The aim of this study was to test the hypothesis that a combination of the well-known and strictly lytic S. aureus phage Sb-1 and oxacillin, which as sole agent is ineffective against MRSA, exerts a significantly stronger bacterial reduction than either antimicrobial alone. Eighteen different MRSA isolates and, for comparison, five MSSA and four reference strains were included in this study. The bacteria were challenged with a combination of varying dosages of the phage and the antibiotic in liquid medium using five different antibiotic levels and four different viral titers (i.e., multiplicity of infections (MOIs) ranging from 10(−5) to 10). The dynamics of the cell density changes were determined via time-kill assays over 16 h. Positive interactions between both antimicrobials in the form of facilitation, additive effects, or synergism were observed for most S. aureus isolates. These enhanced antibacterial effects were robust with phage MOIs of 10(−1) and 10 irrespective of the antibiotic concentrations, ranging from 5 to 100 µg/mL. Neutral effects between both antimicrobials were seen only with few isolates. Importantly, antagonism was a rare exception. As a conclusion, phage Sb-1 and oxacillin constitute a robust heterologous antimicrobial pair which extends the efficacy of a phage-only approach for controlling MRSA.
format Online
Article
Text
id pubmed-8300854
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83008542021-07-24 Synergy between Phage Sb-1 and Oxacillin against Methicillin-Resistant Staphylococcus aureus Simon, Kevin Pier, Wolfgang Krüttgen, Alex Horz, Hans-Peter Antibiotics (Basel) Brief Report Methicillin-resistant Staphylococcus aureus (MRSA) is a notorious pathogen responsible for not only a number of difficult-to-treat hospital-acquired infections, but also for infections that are community- or livestock-acquired. The increasing lack of efficient antibiotics has renewed the interest in lytic bacteriophages (briefly phages) as additional antimicrobials against multi-drug resistant bacteria, including MRSA. The aim of this study was to test the hypothesis that a combination of the well-known and strictly lytic S. aureus phage Sb-1 and oxacillin, which as sole agent is ineffective against MRSA, exerts a significantly stronger bacterial reduction than either antimicrobial alone. Eighteen different MRSA isolates and, for comparison, five MSSA and four reference strains were included in this study. The bacteria were challenged with a combination of varying dosages of the phage and the antibiotic in liquid medium using five different antibiotic levels and four different viral titers (i.e., multiplicity of infections (MOIs) ranging from 10(−5) to 10). The dynamics of the cell density changes were determined via time-kill assays over 16 h. Positive interactions between both antimicrobials in the form of facilitation, additive effects, or synergism were observed for most S. aureus isolates. These enhanced antibacterial effects were robust with phage MOIs of 10(−1) and 10 irrespective of the antibiotic concentrations, ranging from 5 to 100 µg/mL. Neutral effects between both antimicrobials were seen only with few isolates. Importantly, antagonism was a rare exception. As a conclusion, phage Sb-1 and oxacillin constitute a robust heterologous antimicrobial pair which extends the efficacy of a phage-only approach for controlling MRSA. MDPI 2021-07-13 /pmc/articles/PMC8300854/ /pubmed/34356770 http://dx.doi.org/10.3390/antibiotics10070849 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Simon, Kevin
Pier, Wolfgang
Krüttgen, Alex
Horz, Hans-Peter
Synergy between Phage Sb-1 and Oxacillin against Methicillin-Resistant Staphylococcus aureus
title Synergy between Phage Sb-1 and Oxacillin against Methicillin-Resistant Staphylococcus aureus
title_full Synergy between Phage Sb-1 and Oxacillin against Methicillin-Resistant Staphylococcus aureus
title_fullStr Synergy between Phage Sb-1 and Oxacillin against Methicillin-Resistant Staphylococcus aureus
title_full_unstemmed Synergy between Phage Sb-1 and Oxacillin against Methicillin-Resistant Staphylococcus aureus
title_short Synergy between Phage Sb-1 and Oxacillin against Methicillin-Resistant Staphylococcus aureus
title_sort synergy between phage sb-1 and oxacillin against methicillin-resistant staphylococcus aureus
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300854/
https://www.ncbi.nlm.nih.gov/pubmed/34356770
http://dx.doi.org/10.3390/antibiotics10070849
work_keys_str_mv AT simonkevin synergybetweenphagesb1andoxacillinagainstmethicillinresistantstaphylococcusaureus
AT pierwolfgang synergybetweenphagesb1andoxacillinagainstmethicillinresistantstaphylococcusaureus
AT kruttgenalex synergybetweenphagesb1andoxacillinagainstmethicillinresistantstaphylococcusaureus
AT horzhanspeter synergybetweenphagesb1andoxacillinagainstmethicillinresistantstaphylococcusaureus